| 692 | Humans |
| 402 | Animals |
| 344 | Female |
| 342 | Male |
| 217 | Adult |
| 196 | Mice |
| 194 | Stress |
| 192 | AIDS |
| 173 | Human |
| 151 | Human immunodeficiency virus |
| 135 | Middle Aged |
| 102 | Adolescent |
| 83 | Aged |
| 78 | Public health |
| 78 | Mental health |
| 78 | Depression |
| 73 | Disease Outbreaks |
| 72 | Mice, Inbred C57BL |
| 68 | Child |
| 65 | Surveys and Questionnaires |
| 65 | Coping |
| 63 | Oxidative Stress |
| 63 | Cell Line |
| 61 | Social environment |
| 61 | Influenza, Human (epidemiology) |
| 60 | Influenza, Human (prevention & control) |
| 58 | Orthomyxoviridae Infections (immunology) |
| 53 | Risk Factors |
| 53 | Influenza Vaccines (immunology) |
| 50 | Young Adult |
| 50 | Severe Acute Respiratory Syndrome (epidemiology) |
| 50 | Influenza A virus (immunology) |
| 49 | Severe Acute Respiratory Syndrome (psychology) |
| 45 | Time Factors |
| 45 | Stress, Psychological |
| 44 | Influenza, Human (virology) |
| 43 | United States |
| 43 | Pandemics |
| 43 | Influenza, Human (immunology) |
| 41 | Influenza, Human (complications) |
| 40 | Risk factor |
| 40 | Cells, Cultured |
| 39 | Mice, Inbred BALB C |
| 39 | Dogs |
| 38 | Prevalence |
| 38 | Influenza A Virus, H1N1 Subtype |
| 36 | Oxidative Stress (drug effects) |
| 36 | Orthomyxoviridae Infections (virology) |
| 36 | Aged, 80 and over |
| 35 | Stress, Psychological (immunology) |
| 35 | Stress, Physiological |
| 35 | Review |
| 34 | Follow up study |
| 34 | Disease Models, Animal |
| 33 | Lung (virology) |
| 33 | Betacoronavirus |
| 32 | Lung (pathology) |
| 31 | Treatment |
| 31 | Cross-Sectional Studies |
| 30 | Orthomyxoviridae Infections (metabolism) |
| 30 | Mental disorder |
| 30 | Influenza, Human (metabolism) |
| 30 | Anxiety |
| 29 | Symptomatology |
| 29 | Orthomyxoviridae Infections (pathology) |
| 28 | Signal Transduction |
| 28 | Reactive Oxygen Species (metabolism) |
| 28 | Pneumonia, Viral (psychology) |
| 28 | Epidemiology |
| 28 | Coronavirus Infections (psychology) |
| 27 | Madin Darby Canine Kidney Cells |
| 27 | Host-Pathogen Interactions |
| 27 | Apoptosis |
| 26 | Virus Replication |
| 26 | Stress, Psychological (psychology) |
| 26 | Social support |
| 26 | Pregnancy |
| 26 | Influenza Vaccines (administration & dosage) |
| 26 | Influenza A virus |
| 26 | Influenza A virus (physiology) |
| 26 | Comparative study |
| 25 | Influenza A virus (genetics) |
| 25 | Coronavirus Infections (epidemiology) |
| 25 | China |
| 25 | Adaptation, Psychological |
| 24 | Stress, Physiological (immunology) |
| 24 | Posttraumatic stress disorder |
| 24 | Pneumonia, Viral (epidemiology) |
| 24 | Lung (metabolism) |
| 24 | Disease Outbreaks (prevention & control) |
| 23 | Stress, Psychological (complications) |
| 23 | Influenza A virus (pathogenicity) |
| 23 | Influenza A Virus, H1N1 Subtype (immunology) |
| 23 | Cell Line, Tumor |
| 22 | Influenza, Human (psychology) |
| 22 | Child, Preschool |
| 21 | Vaccination |
| 21 | Stress, Psychological (epidemiology) |
| 21 | Orthomyxoviridae Infections (drug therapy) |
| 21 | Immune response |
| 21 | Gene Expression Regulation |
| 21 | Antibodies, Viral (blood) |
| 21 | Age Factors |
| 20 | Stress Disorders, Post-Traumatic (epidemiology) |
| 20 | Severe Acute Respiratory Syndrome (prevention & control) |
| 20 | Psychosocial factor |
| 20 | Orthomyxoviridae Infections (complications) |
| 20 | Models, Biological |
| 20 | Lung (immunology) |
| 20 | Influenza, Human (drug therapy) |
| 20 | Antiviral Agents (pharmacology) |
| 20 | Antioxidants (pharmacology) |
| 20 | Antioxidants (metabolism) |
| 19 | Woman |
| 19 | Treatment Outcome |
| 19 | Stress Disorders, Post-Traumatic (psychology) |
| 19 | Social Support |
| 19 | Severity of Illness Index |
| 19 | Quality of life |
| 19 | Health Personnel (psychology) |
| 19 | Health Knowledge, Attitudes, Practice |
| 19 | Gene Expression Profiling |
| 19 | Cytokines (metabolism) |
| 19 | Antiviral Agents (therapeutic use) |
| 18 | Temperature |
| 18 | Seasons |
| 18 | Psychological effect |
| 18 | Oxidation-Reduction |
| 18 | Molecular Sequence Data |
| 18 | Chlorocebus aethiops |
| 18 | Antiviral |
| 17 | Virus Replication (drug effects) |
| 17 | Treatment efficiency |
| 17 | Seropositivity |
| 17 | Restraint, Physical |
| 17 | Phosphorylation |
| 17 | Personality |
| 17 | Inflammation |
| 17 | Incidence |
| 17 | Concomitant disease |
| 17 | China (epidemiology) |
| 16 | Viral disease |
| 16 | Stress Disorders, Post-Traumatic (etiology) |
| 16 | South Africa |
| 16 | Retrospective Studies |
| 16 | RNA, Messenger (metabolism) |
| 16 | Psychological distress |
| 16 | Prospective Studies |
| 16 | Mice, Knockout |
| 16 | Mental Health |
| 16 | Life events |
| 16 | Life Change Events |
| 16 | Influenza A virus (metabolism) |
| 16 | Hong Kong (epidemiology) |
| 16 | HIV |
| 16 | Drug addiction |
| 16 | Disease |
| 16 | Blotting, Western |
| 16 | Attitude |
| 15 | Stress, Psychological (etiology) |
| 15 | Stress Disorders, Post-Traumatic (diagnosis) |
| 15 | Reverse Transcriptase Polymerase Chain Reaction |
| 15 | RNA, Messenger (genetics) |
| 15 | Protein Binding |
| 15 | Prevention |
| 15 | Predictive factor |
| 15 | Immunity, Innate |
| 15 | Follow-Up Studies |
| 15 | Epstein Barr virus |
| 15 | Epithelial Cells (virology) |
| 15 | Cohort Studies |
| 15 | Cognition |
| 15 | Chickens |
| 15 | Attitude of Health Personnel |
| 15 | Analysis of Variance |
| 14 | Socioeconomic Factors |
| 14 | Risk taking |
| 14 | Lung (drug effects) |
| 14 | Influenza, Human (therapy) |
| 14 | Influenza, Human (pathology) |
| 14 | Influenza, Human (genetics) |
| 14 | Influenza A Virus, H1N1 Subtype (physiology) |
| 14 | Infant |
| 14 | Hong Kong |
| 14 | HeLa Cells |
| 14 | HIV-1 virus |
| 14 | HEK293 Cells |
| 14 | Gene Expression |
| 14 | Disaster Planning |
| 14 | Animal |
| 13 | eIF-2 Kinase (metabolism) |
| 13 | Young adult |
| 13 | Virus |
| 13 | T-Lymphocytes (immunology) |
| 13 | Survival Analysis |
| 13 | Orthomyxoviridae Infections (veterinary) |
| 13 | Mutation |
| 13 | Mice, Inbred ICR |
| 13 | Influenza Vaccines (therapeutic use) |
| 13 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
| 13 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 13 | Immunopathology |
| 13 | Immunomodulation |
| 13 | Hot Temperature |
| 13 | Homosexuality |
| 13 | Health Status |
| 13 | Health Behavior |
| 13 | Fear |
| 13 | Cross sectional study |
| 13 | A549 Cells |
| 12 | Virus Diseases (metabolism) |
| 12 | Viral Proteins (metabolism) |
| 12 | Viral Nonstructural Proteins (metabolism) |
| 12 | Stigma |
| 12 | Sex Factors |
| 12 | Risk |
| 12 | Personnel, Hospital (psychology) |
| 12 | Orthomyxoviridae (immunology) |
| 12 | Nursing Staff, Hospital (psychology) |
| 12 | NF-kappa B (metabolism) |
| 12 | Influenza in Birds (epidemiology) |
| 12 | Health Surveys |
| 12 | Ethnic group |
| 12 | Epithelial Cells (metabolism) |
| 12 | Corticosterone (blood) |
| 12 | Coronavirus |
| 12 | Chronic Disease |
| 12 | Chemotherapy |
| 12 | Birds |
| 12 | Apoptosis (drug effects) |
| 12 | Antioxidants (therapeutic use) |
| 12 | Acute Disease |
| 11 | Workforce |
| 11 | Viral Load |
| 11 | Trauma |
| 11 | Swine |
| 11 | Superoxide Dismutase (metabolism) |
| 11 | Stress, Physiological (physiopathology) |
| 11 | Sexual behavior |
| 11 | Severe Acute Respiratory Syndrome (transmission) |
| 11 | Severe Acute Respiratory Syndrome (therapy) |
| 11 | Prognosis |
| 11 | Orthomyxoviridae Infections (prevention & control) |
| 11 | Orthomyxoviridae Infections (genetics) |
| 11 | Morbidity |
| 11 | Killer Cells, Natural (immunology) |
| 11 | Influenza, Human (transmission) |
| 11 | Influenza, Human (diagnosis) |
| 11 | Influenza Vaccines |
| 11 | Influenza A virus (isolation & purification) |
| 11 | Influenza A Virus, H5N1 Subtype (pathogenicity) |
| 11 | Influenza A Virus, H1N1 Subtype (drug effects) |
| 11 | Heat-Shock Proteins (metabolism) |
| 11 | Global Health |
| 11 | Evolution |
| 11 | Enzyme Activation |
| 11 | Emotion emotionality |
| 11 | Drug compliance |
| 11 | Disease Susceptibility |
| 11 | Caregivers (psychology) |
| 11 | CD8-Positive T-Lymphocytes (immunology) |
| 11 | Biomarkers (metabolism) |
| 11 | Antibodies, Viral (immunology) |
| 11 | Amino Acid Sequence |
| 11 | Aging (immunology) |
| 10 | stress |
| 10 | Virus Diseases (immunology) |
| 10 | Virulence |
| 10 | Vero Cells |
| 10 | Transcriptome |
| 10 | Transcription Factors (metabolism) |
| 10 | Superoxides (metabolism) |
| 10 | Stress, Physiological (complications) |
| 10 | Species Specificity |
| 10 | Signal Transduction (drug effects) |
| 10 | Sexually transmitted disease |
| 10 | Sex |
| 10 | Severe Acute Respiratory Syndrome (nursing) |
| 10 | Severe Acute Respiratory Syndrome (complications) |
| 10 | Rats |
| 10 | Psychotropic |
| 10 | Psychological well-being |
| 10 | Oxidative Stress (physiology) |
| 10 | Orthomyxoviridae Infections (physiopathology) |
| 10 | Multivariate Analysis |
| 10 | Medical Staff, Hospital (psychology) |
| 10 | Influenza, Human (physiopathology) |
| 10 | Influenza in Birds (virology) |
| 10 | Inflammation (pathology) |
| 10 | Immune system |
| 10 | Hydrogen-Ion Concentration |
| 10 | Family environment |
| 10 | Endoplasmic Reticulum (metabolism) |
| 10 | Depression (psychology) |
| 10 | Depression (epidemiology) |
| 10 | Behavior therapy |
| 10 | Base Sequence |
| 10 | Antiretroviral agent |
| 10 | Age |
| 9 | Up-Regulation |
| 9 | United States (epidemiology) |
| 9 | Toll-Like Receptor 4 (metabolism) |
| 9 | Taiwan (epidemiology) |
| 9 | T-Lymphocyte |
| 9 | Substance abuse |
| 9 | Stress, Psychological (prevention & control) |
| 9 | Stress, Psychological (physiopathology) |
| 9 | Schizophrenia |
| 9 | Regression Analysis |
| 9 | Public Health |
| 9 | Proteome (metabolism) |
| 9 | Posttraumatic syndrome |
| 9 | Population Surveillance |
| 9 | Pneumonia, Viral (drug therapy) |
| 9 | Phylogeny |
| 9 | Phenotype |
| 9 | Orthomyxoviridae Infections (mortality) |
| 9 | Orthomyxoviridae (physiology) |
| 9 | Orthomyxoviridae (metabolism) |
| 9 | Oligonucleotide Array Sequence Analysis |
| 9 | Microwaves |
| 9 | Mental Disorders (epidemiology) |
| 9 | Lung (microbiology) |
| 9 | Influenza Vaccines (adverse effects) |
| 9 | Influenza A Virus, H5N1 Subtype |
| 9 | Infection |
| 9 | Immunological investigation |
| 9 | Herpesvirus hominis |
| 9 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
| 9 | Health |
| 9 | Emotions |
| 9 | Disease Outbreaks (veterinary) |
| 9 | Dietary Supplements |
| 9 | Diagnosis |
| 9 | Data Collection |
| 9 | Cytokines (genetics) |
| 9 | Comorbidity |
| 9 | Cold Temperature |
| 9 | Cognitive therapy |
| 9 | Cell Phone |
| 9 | Antigens, Viral (immunology) |
| 8 | Vaccination (psychology) |
| 8 | T-Lymphocytes (metabolism) |
| 8 | Students (psychology) |
| 8 | Structure-Activity Relationship |
| 8 | Stress, Physiological (metabolism) |
| 8 | Somatic disease |
| 8 | Schizophrenia (etiology) |
| 8 | Risk Assessment |
| 8 | Reactive Oxygen Species |
| 8 | RNA-Binding Proteins (metabolism) |
| 8 | RNA, Viral (metabolism) |
| 8 | Quarantine (psychology) |
| 8 | Psychology |
| 8 | Proteomics |
| 8 | Poverty |
| 8 | Pandemics (prevention & control) |
| 8 | Pain |
| 8 | Orthomyxoviridae |
| 8 | Orthomyxoviridae Infections (epidemiology) |
| 8 | Occupational Diseases (epidemiology) |
| 8 | Mortality |
| 8 | Minority |
| 8 | Mice, Transgenic |
| 8 | Malignant tumor |
| 8 | Interviews as Topic |
| 8 | Interferon-gamma (biosynthesis) |
| 8 | Interferon-beta (metabolism) |
| 8 | Influenza, Human (mortality) |
| 8 | Influenza in Birds (prevention & control) |
| 8 | Influenza A virus (drug effects) |
| 8 | Influenza A Virus, H3N2 Subtype (immunology) |
| 8 | Inflammation (immunology) |
| 8 | Infection Control (methods) |
| 8 | Immunosuppression |
| 8 | Hemopathy |
| 8 | Health staff |
| 8 | Health Personnel (statistics & numerical data) |
| 8 | HSP70 Heat-Shock Proteins (metabolism) |
| 8 | Evaluation |
| 8 | Dementia |
| 8 | Cytokines (immunology) |
| 8 | Cytokines (biosynthesis) |
| 8 | Cricetinae |
| 8 | Cellular immunity |
| 8 | Cell Nucleus (metabolism) |
| 8 | Cause of Death |
| 8 | Case-Control Studies |
| 8 | Brain (metabolism) |
| 8 | Attitude to Health |
| 8 | Anxiety disorder |
| 8 | Anxiety (epidemiology) |
| 8 | Antioxidants (administration & dosage) |
| 8 | Antibody Formation (immunology) |
| 8 | Antibodies, Viral (biosynthesis) |
| 7 | Virus Diseases (etiology) |
| 7 | Viral hepatitis C |
| 7 | Viral Nonstructural Proteins (genetics) |
| 7 | Viral Envelope Proteins (metabolism) |
| 7 | Transcription, Genetic |
| 7 | Survivors (psychology) |
| 7 | Socioeconomic status |
| 7 | Sexual abuse |
| 7 | Severe Acute Respiratory Syndrome (virology) |
| 7 | SARS |
| 7 | Respiratory Distress Syndrome, Adult (therapy) |
| 7 | Real-Time Polymerase Chain Reaction |
| 7 | Radio Waves |
| 7 | Quarantine |
| 7 | Psychometrics |
| 7 | Practice Guidelines as Topic |
| 7 | Pneumonia (drug therapy) |
| 7 | Plant Extracts (pharmacology) |
| 7 | Orthomyxoviridae Infections (enzymology) |
| 7 | Nurses (psychology) |
| 7 | Mood disorder |
| 7 | Mitogen-Activated Protein Kinases (metabolism) |
| 7 | Microscopy, Electron, Transmission |
| 7 | Membrane Proteins (metabolism) |
| 7 | Malondialdehyde (metabolism) |
| 7 | Macrophages (metabolism) |
| 7 | Lung (enzymology) |
| 7 | Logistic Models |
| 7 | Liver (metabolism) |
| 7 | Lipid Peroxidation |
| 7 | Lipid Peroxidation (drug effects) |
| 7 | Interleukin-6 (metabolism) |
| 7 | Interleukin-6 (blood) |
| 7 | Influenza, Human |
| 7 | Influenza A Virus, H5N1 Subtype (immunology) |
| 7 | Influenza A Virus, H1N1 Subtype (genetics) |
| 7 | Inflammation Mediators (metabolism) |
| 7 | Inflammation (metabolism) |
| 7 | Infectious Disease Transmission, Patient-to-Professional (prevention & control) |
| 7 | Immunologic Memory |
| 7 | Immunohistochemistry |
| 7 | Immunity |
| 7 | Immune Tolerance (immunology) |
| 7 | Immobilization |
| 7 | Herpes |
| 7 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
| 7 | Hemagglutinin Glycoproteins, Influenza Virus (chemistry) |
| 7 | Health Personnel |
| 7 | Germany |
| 7 | Genotype |
| 7 | Gene Knockdown Techniques |
| 7 | Fibroblasts (metabolism) |
| 7 | Exposure |
| 7 | Europe (epidemiology) |
| 7 | Enzyme-Linked Immunosorbent Assay |
| 7 | Drug combination |
| 7 | Drug Stability |
| 7 | Down-Regulation |
| 7 | Dose-Response Relationship, Drug |
| 7 | Disease Transmission, Infectious (prevention & control) |
| 7 | Cortisol |
| 7 | Communication |
| 7 | Canada |
| 7 | Canada (epidemiology) |
| 7 | CD4-Positive T-Lymphocytes (immunology) |
| 7 | Biomarkers |
| 7 | B-Lymphocytes (immunology) |
| 7 | Autophagy |
| 7 | Association |
| 7 | Anxiety (psychology) |
| 7 | Antiviral Agents (metabolism) |
| 7 | Antibody |
| 6 | inflammation |
| 6 | depression |
| 6 | Vulnerability |
| 6 | Virus Replication (physiology) |
| 6 | Viral Proteins (chemistry) |
| 6 | Violence |
| 6 | Vaccines, Inactivated (immunology) |
| 6 | Vaccination (statistics & numerical data) |
| 6 | Vaccination (methods) |
| 6 | Vaccination (adverse effects) |
| 6 | United Kingdom |
| 6 | Tumor Necrosis Factor-alpha (metabolism) |
| 6 | Treatment compliance |
| 6 | Stress, Psychological (metabolism) |
| 6 | Stress management |
| 6 | Spectrometry, Fluorescence |
| 6 | Sociodemographic factor |
| 6 | Social interaction |
| 6 | Singapore (epidemiology) |
| 6 | Signal Transduction (physiology) |
| 6 | Severity score |
| 6 | Severe Acute Respiratory Syndrome (metabolism) |
| 6 | Self esteem |
| 6 | Self disclosure |
| 6 | School age |
| 6 | SARS Virus (metabolism) |
| 6 | Respiratory Tract Infections (virology) |
| 6 | Respiratory Tract Infections (immunology) |
| 6 | Relapse |
| 6 | Reference Values |
| 6 | Recurrence |
| 6 | Psychotherapy |
| 6 | Psychoneuroimmunology |
